CompletedPHASE1, PHASE2NCT02436928

A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects

Studying Avian influenza

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Medigen Vaccine Biologics Corp.
Principal Investigator
Shan-Chwen Chang, Dr.
National Taiwan University Hospital
Intervention
AT-501 High Dose vaccine(biological)
Enrollment
200 enrolled
Eligibility
20-60 years · All sexes
Timeline
20152016

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02436928 on ClinicalTrials.gov

Other trials for Avian influenza

Additional recruiting or active studies for the same condition.

See all trials for Avian influenza

← Back to all trials